WHO Reference Reagent
Anti-human leukocyte antigen antibodies (negative serum)
NIBSC code: 17/212

Instructions for use

(Version 2.0, Dated 19/05/2023)

This material is not for in vitro diagnostic use

1. INTENDED USE
17/212 is intended for use as a negative control for HLA flowcytometry cross match (FCXM) and single antigen bead Lumexin (SAB-LX) assays performed for detection of anti-HLA alloantibodies. The material was evaluated in an International collaborative study involving 21 participant laboratories conducted for establishment as WHO International reference reagent, WHO-IRR (Rajagopal et al. 2023).

Prior to organ transplantation, assays are performed to detect anti-HLA antibodies that may be detrimental to the performance of the organ. Transplants known to have taken place after a positive FCXM result may have impaired survival (Scornik et al. 2001). Additionally FCXM and Lumexin based anti-HLA screen standardization of the methods used for cross-matching, but also that the selection of the control sera is fundamental to the crossmatch, as they are the negative controls on which the definition of positivity is based (Harmer et al. 1996; Shenton et al. 1997).

17/212 has no assigned unitage and will serve as qualitative intra-assay variability controls, providing a means for trend monitoring for FCXM and LX assays for anti-HLA alloantibody detection. It is not intended for use as calibrator.

2. CAUTION
This preparation is not for administration to humans or animals.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. 2001). Additionally FCXM and Lumexin based anti-HLA screen.

It is therefore important that each user validates this control using their own platform(s). The material is not intended for use in calibration of individual laboratory standards. It is recommended that this standard be used in combination with 21/378: Anti-human leukocyte antigen antibodies (weak positive plasma) or 17/238 Anti-human leukocyte antigen antibodies (strong positive plasma). Users should be aware that by changing assay conditions or reagents e.g. incubation times or secondary antibodies, assay results may vary. FCXM results can vary depending on the donor cells used and set up of the flow cytometer. It is therefore important that each user validates this control using their own methods and reagents. Representative flowcytometry profile is shown in Figure 1.

3. UNITAGE
No assigned unitage.

4. CONTENTS
Country of origin of biological material: United Kingdom. Each vial contains the freeze-dried preparation of approximately 0.5ml of pooled normal human AB+ serum confirmed negative for anti-HLA antibodies in flowcytometry cross match and Lumexin single antigen bead based anti-HLA antibody detection assays. Each unit used for production of this reference reagent was individually tested and found to be negative for presence of HBsAg and antibody to HCV and HIV 1 and 2.

5. STORAGE
Prior to reconstitution, this material has an expiry date of 12/2027. Accelerated degradation studies have indicated that this material is suitably stable when stored at -20°C prior to reconstitution. Reference materials should be stored on receipt as indicated on the label. Once reconstituted, users should determine stability of the material according to their own method of preparation, storage and use. It is recommended this material be used on the day of reconstitution, and no later than 72h after reconstitution.

Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution nor should aliquots be re-frozen after use.

To reconstitute this material, dissolve entire contents of the ampoule in 0.5ml of sterile distilled water, keep at 2-8°C and use within 72h. Product should be centrifuged, and pellet discarded, if presence of cryoprecipitate is noticed upon reconstitution of the freeze-dried material. Once reconstituted, this material should be treated as normal human AB+ serum for use as a negative control for flow cytometry cross matching (FCXM) and Lumexin bead-based assays for anti-HLA alloantibody detection. Different instruments and assays may yield varying results, therefore it is important that each user validates this control using their own platform(s). The material is not intended for use in calibration of individual laboratory standards. It is recommended that this standard be used in combination with 21/378: Anti-human leukocyte antigen antibodies (weak positive plasma) or 17/238 Anti-human leukocyte antigen antibodies (strong positive plasma). Users should be aware that by changing assay conditions or reagents e.g. incubation times or secondary antibodies, assay results may vary. FCXM results can vary depending on the donor cells used and set up of the flow cytometer. It is therefore important that each user validates this control using their own methods and reagents. Representative flowcytometry profile is shown in Figure 1.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials. Stability of the reference reagent is monitored by NIBSC. Users who have data supporting any deterioration in the characteristics of this preparation are encouraged to contact NIBSC.

9. REFERENCES

10. ACKNOWLEDGEMENTS
We are grateful for the valuable contributions of all participants in the collaborative study.

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance: Freeze dried powder</td>
</tr>
<tr>
<td>Stable: Yes</td>
</tr>
<tr>
<td>Hygroscopic: Yes</td>
</tr>
<tr>
<td>Flammable: No</td>
</tr>
<tr>
<td>Other (specify): Contains material of human origin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Toxicological properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of inhalation: Not established, avoid inhalation</td>
</tr>
<tr>
<td>Effects of ingestion: Not established, avoid ingestion</td>
</tr>
<tr>
<td>Effects of skin absorption: Not established, avoid contact with skin</td>
</tr>
</tbody>
</table>

15. LIABILITY AND LOSS
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.
Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY
Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 0.5g
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable. Attached: No

17. CERTIFICATE OF ANALYSIS
NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biolefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.
FIGURE 1: Representative gating strategy used at NIBSC for determining HLA expression on T and B cells. (A) Donor PBMCs are gated for lymphocytes based on scatter profile. (B) Single lymphocytes are identified. (C) Live lymphocytes identified using dead/live dye viability stain are subsequently distinguished (D) as T and B cells using anti-CD3 and anti-CD19 antibodies. Anti-HLA expression is assessed on gated T (E-G) and B cells (H-J) by histogram overlays in comparison to HLA negative RR 7/521 (E-L, blue histogram). Representative profiles for 10/142 (I, J), 17/248 (F, G) and 21/141 (K, J) are shown by the red histogram. (E-J). HLA values for each RR are indicated in the plot. Data depicted for 10/142 are from a separate assay.